Doctor profile · Federal record
Dr. Brundha Balaraman, M.D.
Dermatology Physician (CMS: Dermatology) · Procedural Dermatology Physician · Sugar Land, TX
- NPI 1437461258
- Accepts Medicare
- MIPS 97.1 / 100 · 2023
- 16 yrs in practice
- Female
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
1235 Lake Pointe Pkwy Ste 200
Sugar Land, TX 774784077
(281) 980-0166
fax (281) 980-0177 - Mailing address
-
2950 Cullen Blvd Ste 102
Pearland, TX 775843922
Credentials & registration
- NPI registered
- July 2010 — 16 yrs on file
- Profile last updated
- July 12, 2021
- Year of graduation
- 2010 — 16 yrs since
- Specialty taxonomy
- 207N00000X — NUCC code
- State license (1)
- Texas #Q1085
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1437461258. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
2,841
Distinct HCPCS
10
Medicare allowed
$207,741
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
17003 |
Destruction of precancer skin growth, 2-14 growths | 891 | 132 | $7 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 336 | 187 | $93 | |
11102 |
Biopsy of related skin growth, first growth | 309 | 203 | $93 | |
17000 |
Destruction of precancer skin growth, 1 growth | 270 | 172 | $48 | |
11103 |
Biopsy of related skin growth, each additional growth | 214 | 103 | $52 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 194 | 127 | $132 | |
17110 |
Destruction of skin growth, 1-14 growths | 186 | 126 | $117 | |
99203 |
New patient office or other outpatient visit, 30-44 minutes | 148 | 148 | $116 | |
99204 |
New patient office or other outpatient visit, 45-59 minutes | 110 | 110 | $171 | |
17004 |
Destruction of precancer skin growth, 15 or more growths | 55 | 41 | $176 |
In context: peer comparison
Among 8 peers in this city , average services per provider: 187. This provider delivers 15× the peer median.Open Payments
Industry payments received
All-time total
$967
Transactions
56
Manufacturers
12
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Janssen Biotech, Inc. | 18 | $364.54 | |
| Dermavant Sciences, Inc. | 16 | $134.99 | |
| GENZYME CORPORATION | 5 | $84.67 | |
| Amgen Inc. | 3 | $64.01 | |
| Regeneron Healthcare Solutions, Inc. | 3 | $61.83 | |
| Arcutis Biotherapeutics, Inc. | 3 | $58.06 | |
| Sensus Healthcare, Inc. | 1 | $55.47 | |
| UCB, Inc. | 3 | $54.01 | |
| Incyte Corporation | 1 | $27.47 | |
| ABBVIE INC. | 1 | $24.68 | |
| LEO Pharma Inc. | 1 | $20.19 | |
| PFIZER INC. | 1 | $16.65 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
1,004
Patients
640
Total drug cost
$31,169
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Triamcinolone Acetonide | Generic | 154 | 107 | $2,146 |
| Clobetasol Propionate | Generic | 137 | 78 | $9,127 |
| Ketoconazole | Generic | 129 | 84 | $3,262 |
| Hydrocortisone | Generic | 116 | 95 | $1,140 |
| Mupirocin | Generic | 85 | 58 | $865 |
| Doxycycline Hyclate | Generic | 72 | 46 | $2,339 |
| Fluocinonide | Generic | 46 | 32 | $2,369 |
| Clindamycin Phosphate | Generic | 44 | 21 | $1,497 |
| Fluorouracil | Generic | 44 | 39 | $4,402 |
| Hydroxyzine Hcl | Generic | 41 | 23 | $360 |
Frequently asked questions
What is Dr. Brundha Balaraman's medical specialty?
Dr. Brundha Balaraman practices Dermatology Physician in Sugar Land, TX.
Where does Dr. Brundha Balaraman practice?
Dr. Brundha Balaraman practices at 1235 Lake Pointe Pkwy Ste 200, Sugar Land, TX 774784077. Office phone: 2819800166.
What is Dr. Brundha Balaraman's NPI?
Dr. Brundha Balaraman's National Provider Identifier (NPI) is 1437461258, issued by NPPES.
Does Dr. Brundha Balaraman accept Medicare assignment?
Yes. Dr. Brundha Balaraman accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Brundha Balaraman commonly perform?
Top Medicare-reported procedures in 2023: Destruction of precancer skin growth, 2-14 growths (HCPCS 17003); Established patient office or other outpatient visit (HCPCS 99213); Biopsy of related skin growth, first growth (HCPCS 11102). Source: CMS Medicare Physician & Other Practitioners file.